Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FORAGER-2
2025-522855-25-00Phase 3Authorised
- Sponsor
- Eli Lilly and Company
- Start
- Jul 2026
- Modality
- Small Molecules
- Countries
- 18
01
Overview
Phase 3, randomised, double-blind trial in transitional cell carcinoma (TCC) comparing Vepugratinib triplet arm with Placebo control arm (2 arms). Primary endpoints: Safety and tolerability of vepugratinib in combination with enfortumab vedotin and pembrolizumab, Overall response rate and 1 more. Planned start Jul 2026; status: authorised.
02
Drugs
vepugratinib
03
Conditions
transitional cell carcinoma (TCC)
Beyond the preview
Go deeper on 2025-522855-25-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-522855-25-00.